Breaking New Ground in Alzheimer’s Treatment: A Deep Dive into Lilly’s Kisunla™ (Donanemab-azbt)…

The recent FDA approval of Lilly’s Kisunla™ (donanemab-azbt) for early symptomatic Alzheimer’s disease marks a monumental breakthrough in…